Table 1

Summary of data from blinded assays of sera from patients with ovarian carcinoma and from controls

A. Early stage cancer versus normal
No. of 65 healthy controls exceeding threshold (specificity)No. of 7 early stage cases exceeding threshold (sensitivity)
HE4CA 125
124(0.60)6(0.86)7(1.00)
213(0.80)6(0.86)7(1.00)
38(0.88)6(0.86)7(1.00)
46(0.92)6(0.86)7(1.00)
53(0.96)6(0.86)5(0.71)
60(1.00)3(0.43)2(0.29)
B. Late stage cancer versus normal
No. of 65 healthy controls exceeding threshold (specificity)No. of 30 late stage cases exceeding threshold (sensitivity)
HE4CA 125
124(0.60)29(0.97)28(0.93)
213(0.80)29(0.97)26(0.87)
38(0.88)28(0.93)26(0.87)
46(0.92)25(0.83)25(0.83)
53(0.96)24(0.80)24(0.80)
60(1.00)16(0.53)14(0.47)
C. All cases versus benign disease
No. of 19 benign controls exceeding threshold (specificity)No. of 37 cases exceeding threshold (sensitivity)
HE4CA 125
18(0.60)29(0.97)26(0.87)
24(0.80)29(0.97)24(0.80)
33(0.88)23(0.77)24(0.80)
42(0.92)21(0.70)22(0.73)
51(0.96)20(0.67)12(0.40)
60(1.00)18(0.60)4(0.13)